Regarding the most commonly mutated pathway in NPC, a single drug or a combination of drugs targeting the PI3K/Akt/mTOR signaling pathway has been clinically used or studied in preclinical trials. This evidence concerns the gene AKT1 and nasopharyngeal carcinoma.